Treatment response, ITT population*
| Response . | Arm A, azacitidine + durvalumab n = 64 n (%) [95% CI] . | Arm B, azacitidine n = 65 n (%) [95% CI] . |
|---|---|---|
| ORR (CR + CRi) | 20 (31.3) [19.89-42.61] | 23 (35.4) [23.76-47.01] |
| CR | 11 (17.2) [7.94-26.43] | 14 (21.5) [11.54-31.53] |
| CRi | 9 (14.1) [5.55-22.58] | 9 (13.8) [5.45-22.24] |
| PR | 4 (6.3) [0.32-12.18] | 2 (3.1) [0.0-7.28] |
| HI | 27 (42.2) [30.09-54.29] | 25 (38.5) [26.63-50.29] |
| SD | 23 (35.9) | 21 (32.3) |
| Response . | Arm A, azacitidine + durvalumab n = 64 n (%) [95% CI] . | Arm B, azacitidine n = 65 n (%) [95% CI] . |
|---|---|---|
| ORR (CR + CRi) | 20 (31.3) [19.89-42.61] | 23 (35.4) [23.76-47.01] |
| CR | 11 (17.2) [7.94-26.43] | 14 (21.5) [11.54-31.53] |
| CRi | 9 (14.1) [5.55-22.58] | 9 (13.8) [5.45-22.24] |
| PR | 4 (6.3) [0.32-12.18] | 2 (3.1) [0.0-7.28] |
| HI | 27 (42.2) [30.09-54.29] | 25 (38.5) [26.63-50.29] |
| SD | 23 (35.9) | 21 (32.3) |
Defined as all randomized patients.